Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

AhR and Cancer: from Gene Profiling to Targeted Therapy

Version 1 : Received: 6 November 2020 / Approved: 8 November 2020 / Online: 8 November 2020 (16:16:29 CET)

How to cite: PARIS, A.; TARDIF, N.; GALIBERT, M.; CORRE, S. AhR and Cancer: from Gene Profiling to Targeted Therapy. Preprints 2020, 2020110261 (doi: 10.20944/preprints202011.0261.v1). PARIS, A.; TARDIF, N.; GALIBERT, M.; CORRE, S. AhR and Cancer: from Gene Profiling to Targeted Therapy. Preprints 2020, 2020110261 (doi: 10.20944/preprints202011.0261.v1).

Abstract

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that has been shown to be an essential regulator of a broad spectrum of biological activities required for maintaining the body's vital functions. AhR also plays a critical role in tumorigenesis. Its role in cancer is complex, encompassing both pro- and anti-tumorigenic activities. Its level of expression and activity are specific to each tumor and patient, increasing the difficulty of understanding the activating or inhibiting roles of AhR ligands. We explored the role of AhR in tumor cell lines and patients using genomic data sets and discuss the extent to which AhR can be considered as a therapeutic target.

Subject Areas

AHR; Cancer; Gene Profiling; Therapeutic

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.